Navigation Links
ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India

FREDERICK, Md., April 8, 2008 /PRNewswire/ -- ImQuest scientists Robert W. Buckheit, Jr., Ph.D. and Karen M. Watson, M.S. presented the results of studies performed with products licensed by ImQuest Life Sciences, Inc. at the recent Microbicides 2008, an international conference held in New Delhi, India and attended by microbicide scientists, developers, and care givers from around the world. Dr. Buckheit was invited to speak by the Conference organizers, presenting the results of ImQuest's current research on the pyrimidinedione series of microbicide candidates in a special symposium entitled "New Approaches to Microbicide Candidates". ImQuest is currently developing the highly unique, dual acting pyrimidinediones as potential microbicide candidates based on their significantly high potency against HIV-1, their unique mechanism of action, and their ability to potently suppress the sexual transmission of wild type and drug resistant viruses.

According to Dr. Buckheit (Executive Vice President and Chief Scientific Officer of ImQuest Life Sciences, Inc., and President of its subsidiary, ImQuest BioSciences, Inc.), "It was highly gratifying to speak on our novel pyrimidinedione products at this Conference and to have them recognized as a new approach to HIV prevention by the thousands of dedicated people leading these efforts around the world." ImQuest has obtained funding from the National Institutes of Health and The International Partnership for Microbicides to further develop these products.

At the conference, Ms. Watson (Manager, Topical Microbicide Research and Development) presented three papers, including additional data on the pyrimidinedione IQP-0528, newly emerging data on the microbicide candidate ISIS 5320 (IQP-0831), and results from laboratory studies performed using ImQuest's recently developed Microbicide Transmission and Sterilization Assay which quantifies the ability of microbicide products to completely suppress the sexual transmission of HIV.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in the preclinical and clinical development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective and anti-cancer drug and vaccine development services to the biotechnology and pharmaceutical industry. Both companies are highly involved in efforts to develop an effective anti-HIV topical microbicide.

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.

Executive Vice President and Chief Scientific Officer

ImQuest Life Sciences, Inc.


SOURCE ImQuest Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
2. Neuroscientists Offer Hope for Breast Cancer Patients Suffering From Chemobrain
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, 2016 ... mobile pulmonary function testing company, is now able to perform sophisticated ... by ndd Medical Technologies , Inc. Patients ... hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL patients ... get any needed testing done in the comfort of her own ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):